Selank
Selank (10mg)
$50USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.228
Reference number
10mg
Lyophilized vial
Synthetic analog of the immunoglobulin G-associated tetrapeptide tuftsin. Developed at the Institute of Molecular Genetics, Russian Academy of Sciences.
Origin
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by Myasoedov, Ashmarin, and colleagues. It is a synthetic analog of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide derived from the Fc domain of immunoglobulin G, extended with a C-terminal Pro-Gly-Pro sequence for metabolic stability.
Research Lineage
Selank was registered as a pharmaceutical in Russia in 2009 for anxiety and neurasthenic conditions. Kozlovskii et al. and Seredenin et al. have published on its anxiolytic and nootropic properties in rodent models. Like Semax, it employs the Pro-Gly-Pro stabilization strategy developed by the same research group, and represents the anxiolytic counterpart to Semax's nootropic profile.
Mechanism of Action
Selank has been observed to modulate GABA-ergic neurotransmission and affect the expression of BDNF and its receptor TrkB in hippocampal models. It has also been investigated for effects on enkephalin metabolism and IL-6 expression. The tuftsin core sequence is associated with phagocyte activation and immune modulation, while the Pro-Gly-Pro extension provides CNS-relevant stability.
Structural Notes
Heptapeptide. Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (tuftsin analog with C-terminal Pro-Gly-Pro). Molecular weight: 751.87 Da.
Key References
Kozlovskii II et al. Bull Exp Biol Med. 2003;136(5):451-3.
Seredenin SB et al. Bull Exp Biol Med. 2002;133(5):456-8.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.